Lisen announces an innovative and ground-breaking epigenetics-based diagnostic solution for early lung cancer detection. The clinical research was published in the Clinical Epigenetics on December 14. The new diagnostic method was based on the QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) technology developed by Lisen, which can intuitively translate the biallelic and multiallelic expression status of cancer-related imprinted genes into visualized signals in the nuclei thereby allowing the objective clinical quantification of cancer cell allelic expressions. The present study particularly focused on lung cancer, which has the highest reported mortality among all cancers. With 431 cases overall in the study, QCIGISH achieved 99% sensitivity and 92% specificity in preoperative cytological diagnosis. High sensitivity was especially demonstrated for early-stage lung cancers (including carcinoma in situ, stage Ia and Ib) and small pulmonary nodules (with diameters less than 2 cm), which was significantly higher than preoperative cytopathology. This method could greatly improve the diagnostic performance of preoperative cytopathology, promote the early diagnosis and treatment of lung cancer, and increase the survival of lung cancer patients. The paper was a collaborative work between Lisen and researchers from various medical universities and centers including Ohio State University, Johns Hopkins University, Fudan University, Shanghai Jiaotong University, Qingdao University, Dalian Medical University, Chinese Navy Medical University, Affiliated Zhongda Hospital of Southeast university and Nanjing First Hospital. The paper's primary author was Dr. Zhou Jian from the Shanghai Respiratory Research Institute, Zhongshan Hospital of  Fudan University. Dr. Chunxue Bai, chief physician and professor of Zhongshan Hospital of Fudan University, and Dr. Ning Zhou, Lisen's CEO and co-founder, were the corresponding authors. The official company press release issued by Lisen was also reported by Yahoo and Biospace, among others.